JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

More Than Three Years of Hepatic Recurrence-Free Survival After Radiofrequency Ablation for Hepatic Metastasis From Triple-Negative Breast Cancer

  • 0Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN.
Cureus +

|

August 27, 2025

|

August 27, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Radiofrequency ablation (RFA) offers a promising treatment for triple-negative breast cancer (TNBC) with liver metastasis. This case study shows RFA prevented recurrence for over three years, improving patient quality of life.

Area Of Science

  • Oncology
  • Hepatology
  • Interventional Radiology

Background

  • Triple-negative breast cancer (TNBC) with liver metastasis has a poor prognosis.
  • Current advanced therapies like PARP inhibitors and immune checkpoint inhibitors are not suitable for all TNBC patients.
  • Identifying effective treatment options for metastatic TNBC remains a clinical challenge.

Observation

  • A 70-year-old woman with TNBC and liver metastasis underwent radiofrequency ablation (RFA).
  • The patient received subsequent chemotherapies (eribulin mesylate, gemcitabine) with manageable side effects.
  • She maintained a good quality of life throughout the treatment period.

Findings

  • The patient experienced no recurrence of liver metastasis for over three years post-RFA.
  • Radiofrequency ablation (RFA) demonstrated durable local control of hepatic metastasis in this TNBC case.
  • The combination of RFA and chemotherapy provided a favorable outcome with preserved quality of life.

Implications

  • Radiofrequency ablation (RFA) may represent a valuable therapeutic option for select patients with TNBC liver metastasis.
  • RFA could be considered when targeted therapies are not indicated or feasible.
  • Further research into RFA's role in managing metastatic TNBC is warranted to explore its broader applicability and long-term efficacy.

Keywords: